Literature DB >> 769632

Normal disposition of oxazepam in acute viral hepatitis and cirrhosis.

H J Shull, G R Wilkinson, R Johnson, S Schenker.   

Abstract

Oxazepam (Serax) is a tranquilizer-sedative of the benzodiazepine group that is predominantly metabolized to a pharmacologically inactive glucuronide and subsequently excreted by way of the kidneys. We administered this drug as a single oral dose to seven patients with acute viral hepatitis, to six with cirrhosis, and to age-matched control subjects. Elimination half-life (T1/2) and the apparent oral plasma clearance for the drug in patients with hepatitis and cirrhosis were comparable to values obtained in age-matched controls (P greater than 0.05). In addition, the apparent volume of distribution of oxazepam, its plasma binding, blood/plasma ratio, and the rate of urinary excretion of oxazepam, predominantly as the glucuronide, were comparable (p greater than 0.05) in the two groups of patients with liver disease and their respective controls. Unlike many other sedatives, oxazepam is eliminated normally in patients with parenchymal liver disease an therefore, on pharmacokinetic grounds, seems to be an excellent sedative for use in such persons.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 769632     DOI: 10.7326/0003-4819-84-4-420

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  69 in total

Review 1.  The use of psychotropics in the medically ill.

Authors:  M J Robinson; J L Levenson
Journal:  Curr Psychiatry Rep       Date:  2000-06       Impact factor: 5.285

Review 2.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis.

Authors:  J I Macdonald; S M Wallace; V Mahachai; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

5.  Single dose pharmacokinetics and pharmacodynamics of oral loprazolam in the elderly.

Authors:  C G Swift; M R Swift; S I Ankier; A Pidgen; J Robinson
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

6.  Sterol and bile acid metabolism after short-term prednisolone treatment in patients with chronic active hepatitis.

Authors:  Y Yamanishi; Y Nosaka; H Kawasaki; C Hirayama; S Ikawa
Journal:  Gastroenterol Jpn       Date:  1985-06

Review 7.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

Review 8.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 9.  Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations.

Authors:  J H Kanto
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

10.  Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate.

Authors:  R I Shader; D J Greenblatt; D A Ciraulo; M Divoll; J S Harmatz; A Georgotas
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.